Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.
🇮🇳 India Edition • Healthcare, Pharma & Life SciencesRDU GLOBAL CORRESPONDENT
VERIFIED WIRE INTELLIGENCE
"Motilal Oswal Sees Aster DM EBITDA Rising 25% CAGR Through FY28, Sets Rs 910 Target"
Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.
Motilal Oswal Sees Aster DM EBITDA Rising 25% CAGR Through FY28, Sets Rs 910 Target
R
RDU Global Wire
Macro Economy & Fiscal Policy Desk
New Delhi, India Just now (12:26 PM IST)•5 min read
Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.
Editorial & Verification Notice
Reported by RDU Global Correspondent. Formatted and verified using real-time institutional and journalistic wire feeds. Independent reporting adhering to the RDU Global Editorial Code of Conduct.
Related Coverage
Healthcare, Pharma & Life Sciences
15 Nov 2026, 02:00 PM ISTIndia Launches Statewide Drive to Protect Children Against Tetanus and Diphtheria
India has begun a statewide vaccination drive aimed at strengthening protection for children aged 10 and 16 against tetanus and diphtheria, two potentially serious vaccine-preventable diseases. The initiative builds on early-life immunisation coverage, with officials emphasising that the TD vaccine provides an additional shield after children receive Pentavalent vaccines in infancy.
Healthcare, Pharma & Life Sciences
14 Nov 2026, 08:00 PM ISTCCI Approves Rasmalai Limited’s Acquisition of Stake in Yatharth Hospital and Trauma Care Services
India’s competition regulator has cleared Rasmalai Limited’s proposed acquisition of certain shareholding in Yatharth Hospital and Trauma Care Services Limited, removing a key regulatory hurdle for the transaction. The approval signals that the deal does not raise competition concerns significant enough to warrant intervention under the current review framework.
Healthcare, Pharma & Life Sciences
14 Nov 2026, 02:00 PM ISTKerala High Court Says Police Fully Empowered to Tackle Drug Abuse in City
The Kerala High Court has clarified that police retain full authority to maintain vigilant oversight of drug and substance abuse-related activity in the city. The court said directions issued by a Single Bench would not prevent law enforcement from exercising the necessary watchfulness and action required to curb the menace.